top of page

Search Results

Search this site

92 results found with an empty search

  • Notes from Italian Tech Week 2025 | Sciopolis

    10 Oct 2025 Notes from Italian Tech Week 2025 Reflection from Italian Tech Week by Cat Rigoni, Director of Marketing & Ecosystem, Sciopolis I was at Italian Tech Week in Turin last week, and I’ve been buzzing with ideas since. So many glimpses into a near and fast-approaching future, so many reasons to feel optimistic. But one thought has stayed with me more than any other: AI is no longer just the how , it’s becoming the what . That shift, from enabler to essence, is already reshaping how innovation happens in healthcare, and the Evening Standard article earlier this week reminded me of it: 👉 Doctors swapping stethoscopes for startups — The story of Cera, founded by Dr Ben Maruthappu, is particularly telling. What began as a marketplace connecting carers has evolved into a fully integrated homecare model powered by AI, where data, logistics, and service delivery merge into one intelligent system. Domain expertise as the new differentiator The article also underscored something we don’t talk about enough: domain expertise is the new frontier of innovation. A lot of the talks in Turin were about AI “unencumbering humanity” from menial tasks, from legacy and from infrastructure: a real industrial revolution, which is in constant acceleration towards us. Clinicians who turn founders, often out of frustration with the slow-moving reality of the NHS, bring a rare combination of depth and urgency. They understand patient journeys, system inefficiencies, and the human cost of delay. And when that knowledge and domain expertise is freed from the weight of legacy infrastructure, innovation can move at the speed of insight. Robotics and the redefinition of surgical work That same re-imagination is happening inside the operating theatre. One of the most riveting sessions in Turin featured Jason Hart and surgeon Filippo Filicori — offering a glimpse into the near future of surgical robotics. It showed, with startling clarity, how precision machines will soon handle the long, intricate, painstaking tasks of surgery, allowing humans to focus only where judgment still matter most. With AI now predicting surgical risks upfront and recommending which parts of an operation it can safely take over, the role of the surgeon is rapidly evolving. Instead of standing for hours in physically demanding positions over a patient, surgeons can operate seated via a VR console, collaborating in real time with colleagues across the globe. They can focus solely on the value-add parts of the procedure: the moments requiring judgment, adaptability and empathy. For routine tasks like suturing? Voilà: press autopilot and let the machine handle it. The surgeon of tomorrow will be less a manual operator and more a conductor of complex systems. The implications are huge in terms of training of resources(quicker thanks to simulators), accessing excellence (easier, if you only need a fraction of the surgeon's time) and equality of care (potentially guaranteed, if you are freed up of geographic constraints and can be operated remotely). A new anatomy of medicine What we’re witnessing is the fusion of biology, code and mechanics into a continuum. AI, once the invisible engine of analysis, is becoming the solution itself. Robotics, once peripheral, is entering the core of clinical work. And humans — doctors, researchers, innovators- are hastily repositioning themselves where machines cannot (yet) reach: at the intersection of judgment, ethics, and imagination. It’s the future, and it’s close. We’re talking years, not decades. But where are we , in this picture? For all the brilliance and excitement during the three day event, one thing felt very absent for me: an honest, philosophical and anthropological conversation about the future of mankind when machines take over. I heard a lot about acceleration, automation, and unencumbering humanity from tasks, but no one attempted as much as a sketch of how we , the humans, fit into this. What is our purpose when we are totally unencumbered? How long before the surgeon doesn't even need to do the value-add bit of the operation? There’s a growing unease in the silence. Are we not talking about it because it would generate panic? Does Jeff Bezos know something we don’t? Is he building subterranean bunkers for a reason? We don’t need blind optimism, we need the right forums to socialise our role in this space, to talk openly about ethics, agency, the price we pay for progress and the kind of society we want to build alongside intelligent machines (if we are allowed to exist, that is). Innovation without introspection risks becoming alienating. Follow us on LinkedIn

  • Feasibility Study: designing the Heart of Innovation in Hammersmith & Fulham | Sciopolis

    10 June 2025 Feasibility Study: designing the Heart of Innovation in Hammersmith & Fulham The new Hammersmith Civic Campus is already turning heads— the distinctive RHSP design, bathed in summer light, is a confident, colourful development that reflects an equally bold vision. As the borough’s leader Stephen Cowan put it during our project briefing: “You decide every day if you want to be the most miserable or the best version of yourself. Working in a place like this inspires you to be creative, to bring energy, to be the most innovative version of yourself.” That’s exactly the kind of environment we aim to help create. With Upstream London, Phase 2 of its Industrial Strategy , Hammersmith & Fulham Council is building on the success of the White City Innovation District – its joint collaboration with Imperial College London. The ambition is to extend its STEM³ innovation formula—science, technology, engineering, maths, medicine, and media—across the entire borough. Creating an “Innovation Borough” is no small feat. It demands a clear-eyed understanding of local strengths and gaps, thoughtful integration of existing assets, and the creation of new infrastructure that complements rather than duplicates. Most importantly, it requires a central place—a visible, vibrant hub where this vision can come to life. That’s where Sciopolis comes in. We’ve been commissioned by Hammersmith & Fulham Council to deliver a Feasibility Study exploring what the “innovation heart” of the Civic Campus could and should be. Over the coming weeks, we’ll be working closely with Councillor Cowan and his team to shape a space that reflects the borough’s ambition and supports its innovation ecosystem. What We are Exploring As with all our feasibility work, we’re focusing on two key dimensions: · The Space: What should the physical environment look and feel like? What kinds of behaviours and interactions should it encourage? How can design support collaboration, creativity, and serendipity? · The Mission and Ecosystem: Who will use this space—and why? How do we attract the right mix of people, organisations, and ideas? What makes this hub distinct, and how does it connect to other local innovation assets? We’ll be mapping the borough’s capabilities, speaking with stakeholders, and identifying emerging needs. Our goal is to propose a space that is inclusive, future-facing, and deeply embedded in the local innovation narrative. Let’s Build This Together This is the kind of project we love: ambitious, collaborative, and rooted in place. But before we start designing solutions, we want to hear from you. 📣 Are you based in Hammersmith & Fulham? Do you work in science, tech, media, or innovation and have ideas about how the Civic Campus could support your work or your community? Are you interested in taking space and being part of this ecosystem? 👉 We’d love to hear from you. Drop us a message and help shape the future of innovation in your borough. 👉Read more about Upstream London: Hammersmith & Fulham’s Industrial Strategy

  • London Spinouts: we are building space for you | Sciopolis

    28 Nov 2025 London Spinouts: we are building space for you Spinouts continue to grow as a mighty Asset Class This month, spinouts have been everywhere , cropping up in reports, events, and the press. No longer niche curiosities tucked away in university corridors, spinouts are emerging as a distinct asset class, blending academic credibility with commercial scalability. Investors are beginning to treat spinouts not just as startups, but as a new category of investment, one that blends science, capital, and resilience. Across London, Europe, and beyond, spinouts are reshaping how we think about innovation and economic value creation. Three reports released in November underline the growing strength of UK spinouts: London’s Life Sciences: spinouts at the core The MedCity Life Sciences Companies to Watch 2025 Report, released at London's Life Sciences Week, revealed a striking fact: 56% of the highlighted companies are spinouts . This isn’t just a statistic, it’s a signal that Universities are proving to be fertile ground for commercial breakthroughs, particularly in life sciences, and spinouts are also a dominant share of London’s innovation pipeline. Additionally: 56% are spinouts : a dominant share of London’s innovation pipeline. The Knowledge Quarter & White City are where the majority are based Commercial traction : spinouts are attracting capital faster than traditional startups. Spinouts are not just participating in London’s Life Sciences ecosystem; they are defining it. Deep Tech 2025: spinouts as a superpower The Dealroom Deep Tech Report 2025 , in partnership with the Royal Academy of Engineering, dedicates an entire chapter to spinouts, and makes some striking points. Spinouts are not just numerous, they’re disproportionately valuable. While they account for 34% of deep tech startups, they represent 37% of total enterprise value, punching above their weight in terms of economic impact. Additionally: They make up 43% of the startups that raised $10 million+ funding . Photonics (64% spinouts) and Quantum (58% spinouts) are the deep tech sectors with the strongest academic ties.. Switzerland & UK dominate Europe’s spinout ranking The Dealroom European Spinouts Report 2025 reveals staggering numbers: deep tech and life sciences spinouts across Europe are valued at $398 billion , creating over 167,000 jobs . Additionally: UK universities (Oxford and Cambridge) claim the two top spots with three others in the top ten (UCL, Imperial and University of Bristol). Switzerland has three locations in the top 10. Value creation by spinouts is accelerating The UK leads for spinout value creation , followed by Germany, Switzerland and France Sciopolis: building the workspace London spinouts need At Sciopolis, we believe spinouts deserve more than recognition, they need space to scale and develop their ideas. That’s why we are building cost‑effective, ready‑to‑occupy lab and office spaces in London at Base One, in partnership with Imperial - and soon in other locations. But this isn’t just about (or for) Imperial spinouts. We want the best biotech, quantum, cleantech, AI spinouts from across London’s universities — UCL, King’s, Queen Mary, Brunel and beyond — to come together in our hubs. By clustering talent, ideas, and capital in shared spaces, we are going to create an environment where spinouts can collaborate, accelerate and ultimately scale. Now is the time to act. If you’re building a spinout, or supporting one, or want to invest in the next cohort of exciting spinouts - join us at Base One Get in touch to bring your venture into our hub, collaborate with London’s brightest minds, and help shape the future of innovation under one roof.

  • Sciopolis appointed as Development Advisor by The Crown Estate | Sciopolis

    19 Mar 2025 Sciopolis appointed as Development Advisor by The Crown Estate Sciopolis has been appointed by The Crown Estate to explore opportunities for new start-up, lab, amenity and events space at Cambridge Business Park, North Cambridge. This will form part of the transformation of Cambridge Business Park to become a gateway to a broader innovation district in the area, combining local social impact with national, mission-led innovation. Sciopolis is now working with The Crown Estate to conduct feasibility studies to reposition existing buildings as an Innovation Hub. This could provide space for early-stage businesses, researchers, academics, industry partners and the wider community to locate and collaborate. Together, the organisations will explore how this Innovation Hub might contribute to the local area, and how they can support growing science and technology sectors, such as Cleantech. Sciopolis was appointed as a Development Adviser for this phase of the project based on its extensive experience in developing innovation hubs and for its focus on establishing effective ecosystems to help tenants scale and grow. The company partners with landlords, universities and local government to either convert existing sites or create new ones. Its mission is to build a network of such hubs across strategic locations in the country, providing much-needed infrastructure to help drive the Government’s Science Superpower mission. Sciopolis is expected to support the development of the site and to operate it, as well as initiate ecosystem-building activities at Cambridge Business Park. Mark Sanders, Chairman of Sciopolis, said: “We are proud to be advising The Crown Estate on creating not just a building, but the start of a long-lasting ecosystem. Working for a purpose driven organisation with a long-term focus is a great privilege and we know that this work has particular significance in The Crown Estate’s ambitious vision for Cambridge Business Park.” Charlie Mitchell, CEO of Sciopolis, added: “We never start from the building; we start from understanding what science and technology innovators need, and build for them. Cambridge has no shortage of talent and ideas, and the city is on the ramp up to boost innovation, so it needs infrastructure to match. This means more labs and more space to converge great minds through open design, thoughtful amenities and a relentless focus on collaboration. Cambridge Business Park is the ideal place for a new hub, and we are laying the groundwork for it to become a success story.” Click here to see the proposal under consultation

  • One Portal Way, Old Oak - Sciopolis Appointment | Sciopolis

    31 July 2025 One Portal Way, Old Oak - Sciopolis Appointment Imperial to launch new scale-up space for science and technology ventures in partnership with Sciopolis, delivering urgently needed affordable lab space for London Imperial College London is progressing the innovation-led regeneration of Old Oak with the launch of a new scale-up space for science and tech firms that delivers urgently needed affordable lab space for London One Portal Way, Old Oak is being delivered through a partnership of Imperial and Sciopolis, specialists in flexible, ready-to-occupy lab and office space. It has been designed to meet the needs of innovative scale-ups and will open its doors in mid-2026 The new facility is part of Imperial’s Old Oak Innovation Cluster , which brings together commercial spaces for innovation-led, high growth businesses and accommodation for more than 1,500 Imperial students and key workers Over the next decade, Imperial plans to transform its assets within the Old Oak area to create London’s new innovation and advanced manufacturing hub Imperial’s campus is part of the Old Oak and Park Royal Opportunity Area, London’s largest brownfield regeneration area, which is being delivered by OPDC, and at the heart of WestTech London, a globally significant innovation ecosystem that is igniting frontier innovation and cementing the UK’s position as a science superpower. Read the full coverage in The Standard Imperial College London is launching a new scale-up space for science and technology ventures, One Portal Way, Old Oak , helping to alleviate London’s shortage of affordable lab space and enabling rapidly growing businesses to remain in London as they scale. This new facility not only addresses the shortage of affordable specialist lab space in London, which threatens to hold back the growth of the UK’s science and tech sectors, particularly for startups looking to scale. It also creates a distinctive offer which enables direct connection and support from the world’s leading STEMB university, giving emerging businesses an unrivalled opportunity to grow at pace. One Portal Way, Old Oak will reinvent an existing building into 55,000 sq ft of fully fitted lab and office space, ready to occupy by a community of up to 30 scale-ups in mid-2026. The new facility is part of Imperial’s Old Oak Innovation Cluster, which brings together commercial spaces for innovation-led businesses and accommodation for more than 1,500 Imperial undergraduate students, staff and key workers. Imperial is partnering with Sciopolis – specialists in flexible, ready-to-occupy lab and office space – to develop and operate the space. Occupiers will benefit from the support of Imperial Incubator, the university’s home for early-stage lab-based companies, who will provide on-site assistance and facilitate connections to Imperial’s innovation ecosystem. Professor Hugh Brady, President of Imperial, said : “The UK, and London specifically, is exceptional at discovery science - but we risk becoming a place where great ideas are born, but cannot grow. One of the most urgent challenges is the lack of specialist, affordable lab and grow-on space. Our new innovation facility in Old Oak is a direct response to this challenge, a flexible, ready-to-use space that combines top-tier lab infrastructure with connection to a global university, creative industries, manufacturing capability and exceptional local, national and international transport connections.” Sciopolis CEO, Charlie Mitchell, said: “We know how challenging it is for startups and scaleups to secure suitable and affordable laboratory space. Speed is of the essence, as many ventures are being held back by the lack of grow-on infrastructure, which is why we are partnering with Imperial and other landlords to rapidly convert well-located, unused office and industrial space into innovation hubs with labs, amenities, and support. These spaces are designed to act as catalysts, attracting innovators and quickly building vibrant communities. One Portal Way, Old Oak is a prime example: a building bursting with potential to transform an area and launch a new chapter for Imperial in Old Oak.” Imperial’s One Portal Way, Old Oak will catalyse the transformation of Old Oak, within London’s largest regeneration zone, and play a role in supporting the major development pipeline for the local area which is being led by OPDC with the close involvement of other strategic partners including Ealing Council. In the future, the wider area will benefit from the Old Oak Common Station superhub, which is set to be the UK’s best-connected rail interchange with HS2, the Elizabeth line, Great Western Main Line and Heathrow Services. Imperial’s Old Oak Innovation Cluster is already well connected to central London and the UK via the Elizabeth line, central line and A40, and adjacent to Park Royal, the UK’s largest industrial area which is home to c.1,700 business and supports over 40,000 jobs. One Portal Way is less than 10 minutes from Imperial’s White City Deep Tech Campus. Located at the heart of WestTech London, the creation of One Portal Way, Old Oak ignites Imperial’s plans for the long-term transformation of its assets in the Old Oak area and supports its commitment to make West London the science and technology growth engine for the UK. WestTech London is an emerging innovation ecosystem that will become a globally recognised powerhouse for investment, economic growth and job creation, cementing the UK’s position as a leader in science and technology. WestTech London is bringing together industry, investors, universities, NHS trusts, local authorities, developers and government to fuel innovation and drive global impact. Ealing Council’s Councillor Kamaljit Nagpal, Ealing Council’s lead member for decent living incomes, added : “Our borough is at the heart of WestTech London and our role as a national centre for science and technology is growing all the time. Our jobs and skills strategy – which is aligned with the National Industrial Strategy and London Growth Plan - highlights science and innovation as a priority growth sector for the borough, which can deliver thousands more well-paid jobs for residents over the coming years. The plans coming to fruition at One Portal Way will bring new businesses here that will help to grow our economy. We look forward to continuing to our joint working with Imperial and OPDC, establishing Old Oak as London’s new town for frontier innovation.” OPDC’s Chief Executive David Lunts says : “OPDC’s regeneration of Old Oak will create a revitalised urban district for West London, bringing major new investment into the local economy alongside thousands of new jobs, affordable homes and transformed public realm. Old Oak will deliver over 8,000 new and affordable homes, 6 acres of green open space and up to 2m sq ft of workspace." Imperial’s Old Oak Campus includes student accommodation and key worker homes, with 1,500 students and staff currently resident in the area, as well as the 9.6 acre Victoria Industrial Estate, which Imperial is repurposing to provide vital prototyping and advanced manufacturing follow-on space for scaling businesses. Imperial has ambitious plans for its assets in the Old Oak area which will support c. 4 million sq ft of additional development, including the long-term redevelopment of the broader 4.5 acre One Portal Way site. Imperial’s redevelopment of the One Portal Way site will deliver a new green heart for Old Oak, including a major new public garden, retail, amenities and services, alongside new homes across various tenures, including student accommodation, and 300,000 sq ft of flexible workspace. For more information about the scale-up space or to book a tour visit sciopolis.co.uk/oneportalway

  • Base One (previously 1 Portal Way) officially opens today | Sciopolis

    9 Sept 2026 Base One (previously 1 Portal Way) officially opens today Base One is London's newest science and technology hub. Owned by Imperial College London and operated by science specialists Sciopolis, Base One is unlocking the future of British advanced manufacturing through the adjacency of affordable R&D facilities and industrial space. Base One (previously 1 Portal Way) launches today offering a blueprint for the growth of advanced manufacturing in Britain by supporting high-growth scientific companies to scale in the UK. The 55,000 sq ft innovation hub offers affordable, high-quality, ready-to-occupy labs and offices for deep tech companies and aims to solve the ‘space problem’ for innovators who have often struggled to find flexible, cost-effective spaces that can adapt with their businesses as they progress from R&D to prototyping and production. Base One, in London’s North Acton, is part of Imperial’s Old Oak Innovation Cluster and sits at the heart of WestTech London, a place-based innovation ecosystem, established and anchored by Imperial, which brings together world-class research, global talent, industry and infrastructure to create jobs, attract investment, drive growth and cement the UK’s position as a leader in science and technology. Base One has been designed for established science ventures which are entering their next stage of growth – whether Imperial spinouts or science-based ventures from anywhere else. Base One’s facilities support ongoing R&D and product development, as well as prototyping and early-stage manufacturing. It is located alongside Grapht Works, Imperial’s dedicated advanced manufacturing facility for companies moving into pilot, demo and commercial manufacturing. Together, these two innovation facilities create a new hub for advanced manufacturing, with innovators able to move seamlessly from lab bench to factory floor – supporting the UK’s mission to reinvent its industrial heritage for the modern age. Howard Dawber, Deputy Mayor for Business and Growth, said: “West London is fast becoming a leading centre for science, technology and advanced manufacturing, and Base One is a fantastic addition to the growing innovation cluster at Old Oak and Park Royal. By giving pioneering companies the affordable, flexible space they need to move from research and development to production, Base One will help more businesses start, grow and scale in London—creating good jobs, attracting investment and supporting a new era of British manufacturing, as we build a better, more prosperous London for everyone.” Base One is open to innovative companies from all science sectors, ranging from biotech to chemistry, cleantech, advanced materials, AI and beyond. The hub offers the expertise of specialist landlord Sciopolis, on the ground support from Imperial Incubator’s lab manager, as well as connection to Imperial’s innovation ecosystem. All occupiers will benefit from connections to Imperial’s world-leading experts and academics, a pipeline of exceptional STEMB graduate talent, access to specialist equipment and facilities, as well as a network of connections to founders, funders and collaborators. Base One occupies a strategic location in a growing innovation area, Old Oak Innovation Cluster. It is minutes from Imperial's White City Campus and Hammersmith Hospital Campus, and borders Park Royal Industrial Estate, London's largest industrial estate, which currently employs more than 40,000 people and has more than a century of manufacturing heritage. It sits within the wider regeneration of Old Oak, the largest regeneration opportunity in London, which is to be transformed by the Old Oak Park Royal Development Corporation and the future Old Oak Common superhub, which will connect HS2, the Elizabeth line and GWR, making it the UK’s third busiest station and offering unique connectivity to innovation clusters across the UK including in Birmingham, Bristol, Oxford and Cambridge. As Base One launches, it welcomes its third occupier Nanomox , who will manufacture and commercialise their pioneering high-transparency zinc oxide, designed for use in mineral sunscreens, cosmetics, rubber and electronics, from the hub. Nanomox joins existing occupiers including women’s intimate health company P.Happi® , sold in Boots, which is manufacturing its microbiome-focused products and Ki 13 , the award-winning cleantech company which has created the world’s most cost-effective solution for converting abundant biomass into green hydrogen and biogenic CO2. Hugh Brady, President, Imperial College London: “As we welcome Base One into WestTech London we strengthen our contribution to the UK’s network of national innovation assets, supporting a truly vibrant innovation ecosystem that’s competitive with the very best in the world. Starting from our base in West London, we are enabling a genuinely national asset, with strong links and partnerships to innovation clusters across the UK, such as the West Midland’s manufacturing base for robotics, AI and deep high-value supply chains, and centres of research excellence in Harwell, Oxford, the Bristol Innovation Arc, Cardiff, and beyond.” “For too long high-growth companies have struggled to find the space they need to scale in the UK”, said Charlie Mitchell, CEO of Sciopolis. “We are responding to this pressing need by creating quality, affordable and read-to-occupy options that enable companies to remain in London, supported by a university-connected in an environment that is engineered for growth. Base One and the wider Old Oak Innovation Cluster are a blueprint for advanced manufacturing in Britain.” “Base One is the only destination in London that enables us to start manufacturing whilst remaining in an ecosystem built for our stage of growth, where we can scale up production alongside likeminded companies solving similar problems.” Said Dr Francisco Malaret, Founder and CEO of Nanomox. “Scaling out of the lab and into hardware engineering for the first time is challenging, Base One and its adjacent advanced industrial site enables us to be co-located with other innovators at similar stages to share learnings,” said Koji Muto, Co-founder and CEO of Ki 13. “North Acton delivers everything we need at this crucial stage in our growth – accessibility, affordability and flexibility.” "We're proud to have our Lab Manager onsite at Base One, supporting every innovator who moves in. Imperial Incubator has always backed early-stage companies: with our presence at Base One, we can now stay with them through the delicate scaling stage too, offering our technical and network expertise as they take their next step" said Graham Hewson, Head of Incubation and Prototyping Space, Imperial College London. Explore Base One, North Acton

  • British Land To Turbocharge Massive Life Sciences and Innovation Drive | Sciopolis

    19 May 2023 British Land To Turbocharge Massive Life Sciences and Innovation Drive

  • University Spinouts ascend as scaleup capital deepens, but is the infrastructure ready? | Sciopolis

    20 Oct 2025 University Spinouts ascend as scaleup capital deepens, but is the infrastructure ready? Two recent developments caught our attention last week: Parkwalk and Beauhurst’s Report on investment trends for UK spinouts in 2025 , and the British Business Bank’s £250m investment into scaleups . In a year where many sectors treaded cautiously, university spinouts surged ahead. Beauhurst’s latest report reveals that equity investment into UK spinouts hit £3.35 billion, up 40% from 2023, with biotech, AI, and quantum technologies leading the charge. Flagship deals like Autolus (£436m) and Bicycle Therapeutics (£435m) show that UK science is not just inventive, it’s investable. Parkwalk call for continued efforts to attract capital to support spinouts to realise the UK’s potential. Adding fuel to the fire, the British Business Bank invested £250 million in 33 tech and life sciences scaleups, over half of which are university spinouts. These companies have collectively raised over £2 billion, and the Bank has now lifted its investment ceiling from £15m to £60m per company, an unprecedented move to support scaleup businesses further into their development. The resurgence of scaleup capital is genuinely encouraging and it’s especially positive to see it flowing toward university spinouts. There’s unanimous recognition that the UK’s global edge in innovation stems largely from the strength of its universities, so it makes complete sense that capital should stay close to these institutions and help capture and scale their output. But capital alone won’t deliver impact. As innovation speeds up, the need for appropriate, immediately available infrastructure becomes critical. Without it, companies risk burning precious funding on workspace fit-outs in isolated locations, far from clusters and support. Sciopolis is designed to prevent that. We’re building spaces that are: Linked to universities , enabling proximity to talent and research Conveniently located in emerging, well connected innovation districts like One Portal Way Affordable and ready to move in , so companies can scale without delay We’re committed to ensuring that spinouts and scaleups have the physical platforms they need to deploy innovation quickly, sustainably and in the right environment. Sciopolis will soon open its first site in London Whether you're a spinout looking for your first lab or a scaleup ready to grow, in sectors spanning Technology, AI, Life Sciences, Cleantech - Sciopolis offer ready-to-occupy lab and office spaces, strategic business connections and curated support services, designed to help you thrive. We work in close partnership with universities and, in addition to providing inspiring and cost effective workspaces, we connect our tenants to the academic expertise, specialist equipment and collaborative opportunities that can help science and tech ventures move from idea to impact. 📍 Coming soon: One Portal Way, North Acton Developed in partnership with Imperial College London, our newest site – opening in June 2026- will offer flexible space and tailored support for ambitious ventures in the heart of WestTech London. Find out more about OnePortalWay here

  • Five Things Every Life Sciences Founder Must Get Right - by David Montgomery | Sciopolis

    Five Things Every Life Sciences Founder Must Get Right - by David Montgomery Early-stage life sciences innovation is entering a period of extraordinary opportunity. Across biotech, MedTech, diagnostics and deep healthtech, scientific capability has never been stronger. Academic spinouts are forming at pace. Capital is more globally mobile than ever. Innovation hubs like Sciopolis are deliberately bringing talent, ready to occupy infrastructure and investors into closer proximity. And yet, most breakthrough science does not become a scalable company. The gap between invention and impact is not usually scientific. It is strategic. In our work with founders and early teams, we see the same inflection points arise again and again. The companies that navigate them well accelerate. The ones that don’t often stall - sometimes quietly, sometimes expensively. Here are five things every life sciences founder must consider early. 1. Who is actually buying this? And why? Founders naturally optimise for scientific novelty or technical performance. But markets do not buy novelty: they buy solutions to funded problems. Healthcare buyers are rarely the end users. Clinicians influence. Patients benefit. But payers, procurement teams, integrated care systems, or pharma partners control budgets. A powerful early question is not “Does this work?” but: • Who writes the cheque? • What line item does it come from? • What does success look like in their system? Companies that clarify this early design very differently, from evidence generation to pricing to geographic prioritisation. 2. Are you building with the end game in mind? Too many companies enter clinical development focused on a single regulatory milestone in a single geography. But clinical strategy, regulatory pathway, reimbursement positioning and commercial sequencing are not separate workstreams. They are one integrated design problem. A trial that secures approval but does not support reimbursement can destroy value. A regulatory shortcut that limits label expansion can constrain future markets. A local strategy that ignores global sequencing can cap valuation. The most successful founders think in systems. They design backwards from long-term scale. 3. Clinical performance alone does not drive adoption In healthcare, adoption is not linear. A technology can be clinically superior and still fail commercially. Why? Because: • It disrupts workflow • It shifts budget between departments • It creates unfunded downstream costs • It lacks a champion within the system • It generates data that no one is incentivised to act upon Understanding how adoption actually happens, in real institutions, under real constraints, is often the difference between pilot projects and sustained revenue. 4. Fundraising is about execution risk, not just technology Investors rarely lose money because the science was not interesting, they lose money because execution risk was misunderstood. Early decks often focus heavily on: • The mechanism • The IP • The unmet need But experienced investors are scanning for something else: • Is there a credible regulatory path? • Is the capital plan realistic? • Is the team capable of navigating complexity? • Is the commercial model scalable? Raising capital without a clear scale-up narrative is expensive and dilutive. Raising capital with one creates leverage. 5. Founder overload is real. And dangerous. Life sciences founders operate in compressed decision environments. Within months, they may need to make high-stakes decisions across: • Regulatory strategy • Clinical design • Health economics • Market access • Hiring • Financing • Partnering Most have deep expertise in one domain, usually science. Very few have experience building companies across multiple healthcare systems, regulatory regimes and funding cycles. The risk is not simply making a wrong decision, it is making a series of uninformed early decisions whose consequences compound quietly over time. This is where basing yourself in an ecosystem like the one Sciopolis is building can help. Innovation hubs such as Base One in North Acton actively curate networks of experienced partners, bringing specialist expertise directly into the ecosystem through structured engagement, events and founder support. PM Life Sciences is part of this partner network: through targeted involvement in the Sciopolis ecosystem, it provides founders with access to hard‑won experience across regulation, reimbursement, clinical strategy and commercialisation. Strategic support at this stage is not about outsourcing leadership. It is about reducing avoidable error, stress‑testing assumptions early and giving founders clearer signal in environments heavy with noise. The translation gap, and how we can help Across innovation ecosystems globally, there is a persistent translation gap between academic excellence and scalable company formation. Brilliant science does not automatically translate into: • Investor-ready narratives • Global regulatory strategy • Reimbursement alignment • Credible commercial pathways Bridging that gap requires experience not only of innovation but of healthcare systems, regulation, market access and global execution. PM Life Sciences was founded by to work precisely at this inflection point. Drawing on deep experience across healthcare systems, regulation, clinical development and commercial strategy in multiple markets, we support founders and early teams to: • Clarify who their real buyer is • Design integrated regulatory and reimbursement pathways • Align clinical evidence with long-term value creation • Build credible investor narratives • Navigate complex ecosystems with confidence We work with biotech, MedTech and diagnostic companies at the stage where early strategic decisions shape long-term outcomes. Our focus is simple: To help innovators move faster, with fewer avoidable missteps and with a clearer line of sight to sustainable value creation. For founders within Sciopolis and across the wider innovation ecosystem, the opportunity is immense. But so is the complexity. Getting the early decisions right is not just helpful, it is compounding. Visit: Base One, labs and office space in North Acton Find out more: PM Life Sciences Consulting

  • Construction Update - Jan 26 | Sciopolis

    27 Jan 2026 Construction Update - Jan 26 We’re excited to share the latest progress at our North Acton site, 1 Portal Way, where we’re shaping the next generation of lab and workspace for London’s science and innovation community. Where We Are Now • The project is just over 50% complete , and we remain firmly on track for a June 2026 opening . • The new front entrance building structure is now up, with the floor now solid and roof works underway, setting the stage for a welcoming, street‑level arrival experience for teams and visitors. • Inside the building, most labs, offices and meeting rooms now have walls in place , giving a clear picture of all the spaces - ideal if you’re starting to imagine where you and your teams could call home. Lab space, first floor • Mechanical and electrical installations are progressing smoothly , including systems critical for high-performance research environments. There’s still time to tailor spaces, so please get in touch early with your specific requirements. • Our new internal atrium has taken shape, creating a bright, central collaboration area that already feels like the heart of the building. We think it looks lovely! The central atrium, connecting floors and creating opportunities for members to interact What’s Coming Next • Work will begin soon on the garden , transforming it into a green, high quality amenity space for outdoor working, meetings and downtime. Think summer BBQs in July. • The interior of the entrance building will soon take shape as we build out the café and main event space, which is capable of hosting up to 80 guests. This is a key social element of the 1 Portal Way proposition which will help support and develop our community. Main Event space, linked to entrance area - capacity for up to 80 people Entrance Cafe, serving barista coffee and hot food. Sensibly Sustainable (at least we try) Sustainability is embedded in everything we do: reusing materials, reducing waste and championing local makers as part of our long‑term, low‑carbon strategy. • Trees from the front of the building have been relocated to the rear garden, preserving mature greenery. Private Garden - ideal for Summer Socials or for our members to eat their lunch. • Refurbished fan coil units from the original building are being reinstalled to reduce waste while maintaining efficiency. • In February, we’re trialling a hemp‑based wall stud system for our reception office—a future‑focused, low‑carbon construction technology. • We’re partnering with local suppliers to repaint the exterior and craft bespoke furniture for our hot‑desk area. Want to see it for yourself? We run site tours every Tuesday and we'd love to show you around. I f you’d like to see the progress first‑hand, explore the future labs and workspaces and get a feel for the growing community at 1 Portal Way book your #TuesdayTour now

  • Record £13.9 billion of R&D funding unveiled to boost innovation | Sciopolis

    9 Apr 2025 Record £13.9 billion of R&D funding unveiled to boost innovation In the thick of all of the economic turmoil, it is welcome news that the Government is committed to supporting research and innovation with the announcement of the allocation of the £13.9 billion Department of Science, Innovation and Technology research and development budget. A path to economic prosperity, better employment prospects for all and the solving of major world challenges must surely be underpinned by research and innovation and taking away the barriers that prevent businesses being formed or that limit their growth and impact will benefit everyone. I’m delighted that funding is available for innovators and entrepreneurs. I hope this will inspire them to innovate and seize the opportunity to create businesses that realise the full potential of their ideas. I also hope that the planned investments will help to create the environment for business success by enabling the infrastructure to support innovators, including incubator and scaleup facilities. Scaleup businesses will surely benefit from access to capital, but by removing the barriers to commercialisation of cutting-edge research and by supporting their growth through appropriate infrastructure, we see the potential for a multiplier effect, where the funding will deliver quicker and better outcomes. Failure to invest in the supporting and enabling ecosystems for scaleup businesses will reduce the benefit of the proposed investment and will ultimately constrain the growth of new firms and the realisation of the benefits of their innovations, limiting their opportunity to be global market leaders of the future. Read the Government R&D Fund announcement here

  • First Tenant announced: Ki 13 | Sciopolis

    30 Mar 2026 First Tenant announced: Ki 13 Welcoming Ki 13 (Previously known as Ki Hydrogen) to Base One A UK cleantech startup with breakthrough green hydrogen technology is set to call our North Acton Innovation Hub home from June 2026. This is what we built 1 Portal Way for. 1,500 SQ FT LAB & OFFICE June 2026 OPENING 55,000 SQ FT TOTAL HUB 24 FITTED LABS AVAILABLE We’re really pleased to announce that Ki 13 — one of the UK’s most promising cleantech startups — will be the first company to take up space at our new Innovation Hub at Base One, North Acton, ahead of our June 2026 opening. Ki 13 will occupy 1,500 sq ft of laboratory and office space, giving their team the room and infrastructure to progress into an engineering scale-up phase — all while staying connected to the Imperial College London ecosystem they grew up in. From a single bench to a fully fitted lab Ki 13’s journey is the kind of story that Base One is designed to support and extend. The company originated within Imperial’s innovation ecosystem, beginning with a single bench at Imperial Incubator in White City. They then moved into dedicated lab space before being selected for the inaugural cohort of EarthScale — the Imperial-led programme supporting pioneering climate tech ventures advancing from prototype to commercial manufacturing — as well as Imperial Undaunted’ s accelerator. Their arrival at Base One is the next chapter: a purpose-built hub where they can scale their technology without leaving the network that has supported them. “Sciopolis offers exactly the kind of environment we need as we progress into our engineering scale-up phase. Remaining within the Imperial and WestTech London ecosystem — while gaining the space, capability and flexibility to scale our technology — is a major advantage. We’re excited to grow here in Old Oak and to contribute to this emerging innovation cluster.” — Koji Muto — Co-founder & CEO, Ki 13 Technology that matters Ki 13 is tackling one of green hydrogen’s most stubborn problems: the enormous amount of energy required to produce it. Green hydrogen is one of the most promising clean fuels on the planet, but it takes a huge amount of electricity to make, which has always kept costs high. Ki 13 has found a smarter way. Instead of using electricity alone, their process combines it with waste biomass: things like leftover wood, straw, and agricultural residues that would otherwise go to waste. The result is green hydrogen produced at a fraction of the usual energy cost. As a bonus, the process also captures biogenic CO₂, itself a valuable ingredient in sustainable aviation fuel and green methanol. So one process, two useful outputs, and a much more viable path to clean industry. Part of a growing cluster Ki 13 ’s arrival at Base One places them at the heart of Imperial’s emerging Old Oak Innovation Cluster. They’ll be neighbours with companies including Solena Materials , based at Imperial’s nearby advanced manufacturing site, Grapht Works. “We’re delighted to see Ki 13 continue to grow. They started with a single bench at Imperial Incubator and then moved into their own dedicated lab space. Now we are looking forward to partnering with Sciopolis at 1 Portal Way and to working with Ki 13 again. Their journey shows exactly what WestTech London is designed to deliver: a place where a startup can launch easily, expand within a supportive community and begin pilot manufacturing locally.” Graham Hewson — Head of Incubation & Prototyping Spaces, Imperial College London Setting the scene for what's to come London has a well-documented shortage of affordable, ready-to-occupy laboratory space. Too many companies at a critical stage in their growth are priced out of the capital just as they’re hitting their stride. Base One exists to change that: offering cost-effective, fully fitted CL2 laboratories and flexible offices, with no upfront capital investment required, embedded in an exciting, university-linked ecosystem. “Ki 13's arrival sets the tone for what Sciopolis stands for: bringing together companies tackling the world’s most urgent challenges, and giving them the space, infrastructure and community support they need to scale and begin manufacturing in London.” — Charlie Mitchell — CEO, Sciopolis Ki 13 is the first member of our community, and it’s a lovely first. We’ll be announcing more tenants in the months ahead as we count down to our June opening. If your company is looking for space to grow, we’d love to talk. Discover our lab and office availabilty Download our Brochure ABOUT KI 13: ki-13.com →

bottom of page